Pediatrix Medical Group stock
MDNYSEPediatrix Medical Group, Inc., HealthcareISIN US58502B1061
70Score 70 out of 100, Strong
Price and trend
87 / 100
Price history
+38% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 4.3% below its 52-week high. Largest decline in 20 years: 92% (August 2015 to June 2024).
Chart figures for advanced users
- SMA 50$27.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.31
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.82
- The lowest closing price of the last twelve months.
- Resistance$32.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pediatrix Medical Group, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $2.45B, is number 27 of 57 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.97B (up 3%) and adjusted earnings per share of $2.41 (up 18.8%).
- MEQIRI Score 70 out of 100 (Strong): rank 140 of 702 in Healthcare, median 53.
Show more
- The P/E is 16.7 (Medical (Care Facilities) median 19.6, own median of recent years 16.8).
- Our model puts fair value at $44.23, with the price 29% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 29% below the fair value of $44.23.Valuation 68
- Earnings turn into cashFree cash flow 140% of earnings over the last 12 months.Fundamentals 77
- High return on capitalReturn on invested capital 16.8% in fiscal 2025, Medical (Care Facilities) median 6.1%.Profitability 61
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis, while growth holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $34.02 and expensive above $63.18 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $51.49 (cash-flow model) and $36.97 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $39.95, at 7.8% it would be $50.65.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.9% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 25%, operating 12%, net 9%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 29 Oct 2026EPS reported $0.72 (expected $0.65)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.41+2.7%
- Revenue
- $1.97B+0.5%
- Earnings per share
- $2.49+2.0%
- Revenue
- $2.02B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.1%Pediatrix narrowed its full year 2026 adjusted EBITDA outlook to $290 million to $300 million after the quarter came in ahead of expectations with $85.5 million of EBITDA.
“We are narrowing the range of our full year 2026 outlook to $290 million to $300 million in adjusted EBITDA.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pediatrix Medical Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- National HealthCareNHC $3.3B68
- Guardian Pharmacy ServicesGRDN $3.13B77
- Aveanna Healthcare HoldingsAVAH $2.67B60
- Ardent HealthARDT $2.49B60
- Addus HomeCareADUS $2.31B70
- Brookdale Senior LivingBKD $2.14B23
- EmeisEMEIS.PA $1.89B41
- Agilon HealthAGL $1.85B49
ETFs that hold Pediatrix Medical Group
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.23% | 0.40% | €807M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.14% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.07% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.05% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.